Intestinal absorption of penclomedine from lipid vehicles in the conscious rat: contribution of emulsification versus digestibility

Smidt, P.C. de; Campanero, Miguel Ángel; Trocóniz, Iñaki F.

doi:10.1016/j.ijpharm.2003.10.036

Cited by 71 publications

(34 citation statements)

References 27 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The significantly greater bioavailability of lutein nanoemulsions could have two explanations: (i) nano-sized lutein particles and (ii) micelle-like matrix of the nano particles. The lutein nanoparticles have a greater probability of being absorbed as they have a greater surface to volume ratio as opposed to lutein in a pill form [31,32]. The 6 mg lutein supplement pill in the present study was in a powder, not oil form.…”

Section: Discussionmentioning

confidence: 91%

Bioavailability of a Nanoemulsion of Lutein is Greater than a Lutein Supplement

Vishwanathan¹,

Wilson²,

Nicolosi³

2009

Nano BioMed ENG

View full text Add to dashboard Cite

Lutein, a lipid soluble, oxygenated carotenoid, has shown beneficial effects against the risk factors associated with age-related macular degeneration, cardiovascular disease and also damaging UV radiation. The goal of the present study was to formulate lutein into a stable hydrophilic nanoemulsion that is more bioavailable and consumable in a matrix such as a beverage rather than just supplements. A Microfluidizer® Processor was used to convert an oil-in-water lutein emulsion into a nanoemulsion that is a stable water dispersion and measures 150 nm. After a one wk baseline phase, subjects consumed a lutein supplement pill followed by a lutein nanoemulsion added to orange juice (6 mg/d and 2 mg/d in two separate studies) for one wk each with a 2 wk washout phase between treatments. In study 1, mean serum lutein concentrations (n = 9) increased by 104% (P < 0.001) and 167% (P < 0.001) after the 6 mg supplement and nanoemulsion phases, respectively. In study 2, mean serum lutein concentrations (n = 11) increased by 37% (P < 0.05) and 75% (P < 0.001) after the 2 mg lutein supplement and nanoemulsion phases, respectively Despite the fact that the actual concentration of lutein in the 6 mg and 2 mg nanoemulsions was 10% and 40% lower compared to the supplement form, respectively, due to Microfluidizer ® processor preparation loss, the nanoemulsions resulted in 31% (P < 0.05) and 28% (P < 0.05) greater serum lutein concentrations compared to the supplement.. In conclusion, nanoemulsions of lutein had significantly greater bioavailability than the supplement-pill forms. Keywords:

show abstract

Section: Discussionmentioning

confidence: 91%

Bioavailability of a Nanoemulsion of Lutein is Greater than a Lutein Supplement

Vishwanathan¹,

Wilson²,

Nicolosi³

2009

Nano BioMed ENG

View full text Add to dashboard Cite

show abstract

“…27,30) In conclusion, the optimal formulation of SMEDDS containing daidzein (high drug loading and small particle size) was as following: Ethyl oleate (10%), Cremophor RH 40 (60%), and PEG400 (30%) due to high affinity for the continuous phase and forming the smallest particle size. In vitro dissolution studies revealed that dissolution of daidzein from SMEDDS was faster than the conventional tablet.…”

Section: Discussionmentioning

confidence: 99%

Enhanced Oral Bioavailability of Daidzein by Self-Microemulsifying Drug Delivery System

Shen

Yuan

et al. 2010

Chem. Pharm. Bull.

View full text Add to dashboard Cite

“…(Patel et al, 2008;Vogt et al, 2008;Yavuz et al, 2010). All these techniques yield limited fruition when the drug exhibits low bioavailability, owing to metabolism by the cytochrome P450 family of enzymes present in the gut enterocytes and liver hepatocytes, instability in gastrointestinal (GI) fluids, restricted intestinal permeability, and/ or P-glycoprotein (P-gp) efflux (de Smidt et al, 2004;Sha et al, 2005;Koga et al, 2006;Constantinides & Wasan, 2007;Hauss, 2007;Singh et al, 2009a). Self-emulsifying drug delivery systems (SEDDS), in this regard, have been gaining world-wide acceptance to improve the bioavailability potential of lipophilic drugs by augmenting their dissolution and permeation, and for bypassing hepatic first-pass effect (Humberstone & Charman, 1997;Porter & Charman, 2001;Sha et al, 2005;Koga et al, 2006).…”

Section: Original Articlementioning

confidence: 99%